Coeptis Therapeutics (COEP) and Its Peers Critical Review

Coeptis Therapeutics (NASDAQ:COEP) is one of 282 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Coeptis Therapeutics to related businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Coeptis Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.42
Coeptis Therapeutics Competitors	$513.84 million	-$40.55 million	6.80

Coeptis Therapeutics’ rivals have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ rivals have a beta of 1.00, suggesting that their average share price is 0% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Coeptis Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	2	0	3.00
Coeptis Therapeutics Competitors	1391	3975	10749	152	2.59

Coeptis Therapeutics presently has a consensus price target of $3.50, indicating a potential upside of 899.71%. As a group, “Biological products, except diagnostic” companies have a potential upside of 68.27%. Given Coeptis Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Coeptis Therapeutics is more favorable than its rivals.

Profitability

This table compares Coeptis Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-4,645.78%	-214.40%	-46.99%

Institutional & Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Coeptis Therapeutics rivals beat Coeptis Therapeutics on 7 of the 13 factors compared.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.